Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Novo Nordisk

Status and phase

Completed

Phase 1

Conditions

Healthy

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: semaglutide

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03144271

2007-000303-15 (EudraCT Number)

NN9535-1820

U1111-1193-6996 (Other Identifier)

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability of ascending single s.c. doses of NNC 0113-0217 in healthy male subjects, aiming at establishing the Maximum Tolerated Dose (MTD)

Enrollment

58 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
Subject is male
Age 18-65 years, both included
Body Mass Index (BMI) below 35.0 kg/m^2 (Body weight between 50 kg -150 kg, both inclusive)
Good general health based on medical history, physical examination including ECG (Electrocardiogram) and laboratory analysis, as judged by the investigator

Exclusion criteria

Previous participation, defined as randomised, in any other clinical trial involving this or other investigational products within the last 3 months before dosing
Patients with MI (Myocardia-Infarction) during the last 12 month
Patients receiving ACE (Angiotensin-Converting Enzyme) inhibitors, beta-blockers, thiazide diuretics, thyroid hormones, and/or lipid lowering medication who are not on a stable dose for more than 6 weeks prior to start of the study
Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine)
Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy)
Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly effective method of contraception (Pearl Index below 1%) such as implants, injectables, combined oral contraceptives, or hormonal IUDs (intrauterine devices), or refrain from sexual intercourse during the study and until 1 month after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by study medication
Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers, and MAO (Mono-Amino-Oxidase) inhibitors
Subjects who drink more than 8 cups of tea/coffee per day
History of drug or alcohol abuse (defined as intake of more than 28 units weekly - 1 unit = 12 oz or 360 ml of beer; 5 oz ir 150 ml of wine; 1.5 oz or 45 ml of distilled spirits)
Alcohol intake within 48 hours prior to dosing
Evidence of drug abuse on urine testing and serum at study entry
The subject smokes 7 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the dosing day and during the confinement period
Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV-positive
Impaired hepatic function measured as ALAT (Alanine aminotransferase), ASAT (Aspartate aminotransferase), alkaline phosphatase above three times the upper reference limit (one retest within one week is permitted, the last result being conclusive)
Clinical significant abnormal laboratory test results during the screening as judged by the Investigator
Impaired renal function, defined as s-creatinine above or equal to 135 μmol/L (=1.5mg/dL) (one retest within one week is permitted, the last result being conclusive)
Cardiac problems defined as: decompensated heart failure (NYHA (New York Heart Association) class III and IV) at any time and/or angina pectoris and/or myocardial infarction within the last 12 months
Blood pressure in supine position at the screening examination above 160 mmHg systolic or 90 mmHg diastolic or heart rate outside the range of 50 - 90 bpm
Known or suspected allergy to trial product or related products
History of significant drug allergy or drug hypersensitivity
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Blood donation or considerable blood loss - more than 500 mL, during the 3 months prior to study start
Any condition that the investigator and / or sponsor feels would interfere with study participation or evaluation of results
Use of non-prescription drugs, except routine vitamins, within 1 week prior to the dose of the test drug. Occasional use of paracetamol is permitted
Subjects who have taken part in strenuous exercise within 4 days prior to trial start, due to interference with the hepatic microsomal mono-oxygenase system. The evaluation whether strenuous exercise has been undertaken will be evaluated by the Investigator, and strenuous exercise is not allowed during the trial